Peripheral Versus Central Cannulation for Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO): A Meta-Analysis of Bleeding and Vascular Complications

February 16, 2026 No Comments

This meta-analysis of 15 studies (2,913 patients) compares peripheral and central cannulation strategies for VA-ECMO in refractory cardiogenic shock. Peripheral access significantly reduced major bleeding risk but increased limb ischemia. No meaningful differences were observed in infection, renal replacement therapy, or stroke. Findings support individualized cannulation decisions balancing bleeding risk against vascular complications.

Preoperative Anemia Management and Its Economic Impact on Red Blood Cell Transfusion in Cardiac Surgery

Predictors and Economic Impact of Red Blood Cell Transfusion in Cardiac Surgery: A Simulated Cost Reduction Model for Preoperative Anemia Management

February 16, 2026 No Comments

This retrospective cohort study of 661 elective cardiac surgery patients identified preoperative anemia as the strongest independent predictor of red blood cell (RBC) transfusion (OR 3.67). Transfusion was associated with longer hospital stay, higher infection rates, prolonged ventilation, and a median cost increase of €2264 per patient. A simulation model estimated that eliminating preoperative anemia could prevent 47 transfusions and save €106 429 over 13 months.

Intravenous Lidocaine Infusion During Cardiopulmonary Bypass Cardiac Surgery

Evaluation of the Effect of Intravenous Lidocaine on the Systemic Inflammatory Response Associated With Cardiopulmonary Bypass in Valvular and/or Coronary Cardiac Surgery: Protocol for a Double-Blind Randomized Clinical Trial

February 16, 2026 No Comments

This single-center, double-blind randomized clinical trial (LEONARD Trial) evaluates whether intravenous lidocaine reduces systemic inflammation triggered by cardiopulmonary bypass in elective valvular and/or coronary cardiac surgery. Ninety patients will receive lidocaine or placebo, with IL-6 at 6 hours postoperatively as the primary endpoint. Secondary outcomes include inflammatory biomarkers, organ dysfunction, atrial fibrillation, ICU stay, opioid use, and 30-day mortality.